CNTB (Connect Biopharma Holdings) Stock Based Compensation: $3.98 Mil (TTM As of Mar. 2026)


CNTB Connect Biopharma Holdings Ltd CNTB
7 GF Score
Price $2.52
! 3 Warning Signs
View Full Analysis

What is Connect Biopharma Holdings Stock Based Compensation?

Connect Biopharma Holdings CNTB -5.82% 7 Stock Based Compensation is $3.98 Mil as of Mar. 2026. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review.

Connect Biopharma Holdings's Stock Based Compensation for the three months ended in Mar. 2026 was $1.20 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $3.98 Mil.

Connect Biopharma Holdings Stock Based Compensation Related Terms

Connect Biopharma Holdings Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Connect Biopharma Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Connect Biopharma Holdings Stock Based Compensation Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 8.99 6.91 5.40 6.73 3.73

Connect Biopharma Holdings Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.95 0.92 0.92 1.20
CNTB
7GF Score
Connect Biopharma Holdings Ltd CNTB
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Connect Biopharma Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.98 Mil.

What does a Stock Based Compensation of $3.98 Mil mean?
Connect Biopharma Holdings (CNTB) has a Stock Based Compensation of $3.98 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Connect Biopharma Holdings and its competitors.
Is Connect Biopharma Holdings' Stock Based Compensation too high?
Connect Biopharma Holdings' current Stock Based Compensation is $3.98 Mil. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' Stock Based Compensation compare to ENLV and SMNR?
Connect Biopharma Holdings' Stock Based Compensation of $3.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Connect Biopharma Holdings and its competitors. Connect Biopharma Holdings's current Stock Based Compensation is $3.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current Stock Based Compensation of $3.98 Mil. The current Stock Based Compensation is $3.98 Mil. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current Stock Based Compensation is $3.98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Connect Biopharma Holdings Business Description

Address 3580 Carmel Mountain Road, Suite 200, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score

Get the complete analysis for CNTB

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.52
Price